Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qianqing Granules is a Class 1.1 innovative Traditional Chinese Medicine (TCM) developed by Hunan Warner Pharmaceutical Co., Ltd. for the treatment of the common cold, specifically targeting the wind-heat syndrome. Approved by China's National Medical Products Administration (NMPA) in December 2023, the formulation is designed to clear heat, release the exterior, and detoxify. Clinical trials have demonstrated its efficacy in reducing symptoms such as fever, sore throat, cough, and yellow phlegm associated with viral upper respiratory tract infections. As a multi-herb preparation, it utilizes a synergistic pharmacological approach to provide symptomatic relief and support the immune response during the acute phase of a cold.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qianqing granules.